While all eyes have been on the Senate, the House has been quietly preparing to address another key issue affecting healthcare.
On Tuesday, the Senate held a procedural vote that will allow a debate over healthcare reform to proceed. The vote came after Senator John McCain (R-Arizona) returned to the Capitol, despite his recent diagnosis of brain cancer, to vote in favor of advancing the bill. Two Republicans, Lisa Murkowski (Alaska) and Susan Collins (Maine) joined Democrats in voting no on the motion to proceed. Republican Senators Shelley Moore Capito (West Virginia), Rand Paul (Kentucky), and Dean Heller (Nevada) had previously expressed reservations about the bill, but voted in favor of advancing the bill to a debate.
Today’s vote allows the Senate to begin amending the narrowly passed House version of the healthcare bill, which is widely expected to emerge as a “skinny repeal” of the Affordable Care Act (ACA), which would make fewer changes to existing law than would the House version of the proposed legislation. Senator McCain, speaking after the vote, said that such a bill would be “imperfect,” but that it “might provide workable solutions to problems that Americans are struggling with today.”
While all eyes have been on the Senate, the House has been quietly preparing to address another key issue affecting healthcare; on Thursday, the House of Representatives Judiciary Committee will hold a hearing titled “Antitrust Concerns and the FDA Approval Process.” The hearing, which will be conducted by the Judiciary’s Subcommittee on Regulatory Reform, Commercial, and Antitrust Law, is expected to deal with proposed legislation to facilitate the development of generics and biosimilars. Inside Health Policy reports that a source familiar with the scheduled hearing expects the proceedings to deal with the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act.
The CREATES Act, which has bipartisan support, would provide access to equivalent samples for testing by biosimilar and generics manufacturers, and would facilitate judicial review in lawsuits concerning innovators’ improper withholding of samples from competitors. The text of the act cites risk evaluation and mitigation strategies (REMS) as both an essential feature of the development of generics and biosimilars and also a potential avenue for abuse by innovators seeking to stifle competition, which the bill calls “contrary to the policy of the United States to promote competition in the market for drugs and biological products.”
Slated to testify at Thursday’s hearing is Scott Gottlieb, MD, commissioner of the FDA. At last week’s public meeting on the Hatch-Waxman Amendments, Gottlieb heard from a variety of stakeholders who criticized the ability of innovators to use REMS to block competitors from obtaining samples. Gottlieb himself has said that he seeks to address concerns surrounding dubious uses of REMS, noting that “some branded companies may be using the statutory default requirement to have a single shared REMS across both the branded and generic versions of a drug as a way to block generic entry. They might prolong negotiations with the generic firms over the implementation of these single shared systems, which could delay the entry of safe and effective generic drugs onto the market.”
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
The Subcutaneous Revolution: Zymfentra and the Future of IBD Care With Dr Andres Yarur
December 17th 2023On this episode of Not So Different, Andres Yarur, MD, a researcher and associate professor of medicine at Cedars-Sinai Medical Center, discusses the significance of the FDA approval for Zymfentra, the world's first subcutaneous infliximab product, for patients with inflammatory bowel disease (IBD).
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
Biosimilars Council: PBM Rebate Schemes Cost Americans, Payers $6 Billion
April 10th 2024A report from the Biosimilars Council evaluating IQVIA data found that rebate schemes orchestrated by pharmacy benefit managers (PBMs) are costing US patients and payers billions of dollars by suppressing biosimilar adoption.